CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-08-17
Credit Expiration Date: August-08-18


Joseph R. Mikhael MD, MEd, FRCPC, FACP
Professor of Medicine
Mayo College of Medicine
Associate Dean
Mayo School of Graduate Medical Education
Deputy Director - Education
Mayo Clinic Cancer Center
Phoenix, AZ

Additional Content Development Faculty
Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders
Director, Clinical Research in Hematologic Malignancies
Clinical Professor of Medicine UNC-Chapel Hill School  of Medicine
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute/ Carolinas HealthCare System
Charlotte, NC

Ajai Chari, MD, PhD
Associate Professor of Medicine
Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

Credit Hours



Online Presentation

Program Description

The treatment landscape for multiple myeloma (MM) is rapidly evolving. This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma.

Program Developer/Facilitator


Target Audience

Community medical oncologists, radiation oncologists, hematologists, hematologist/oncologists, internists, oncology nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians involved in the management of patients with MM.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss new treatment options stemming from recent FDA approvals in the relapsed/refractory setting.
  2. Review recently published clinical trial data on the efficacy and safety of emerging treatments for relapsed/refractory patients.
  3. Describe recent changes to clinical practice guidelines affecting care for patients with relapsed/refractory disease.
  4. Summarize best practices with respect to communication and coordination among members of the multidisciplinary myeloma care team.


It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Dr. Mikhael has disclosed the following:
Research Grant: AbbVie, Celgene, Sanofi

Dr. Usmani has disclosed the following:
Speakers Bureau: Amgen, Celgene, Takeda
Consultant/Advisor: Amgen, Celgene, Janssen, SkylineDX
Research Grant: Amgen, Celgene, Janssen, Takeda, Sanofi, Array BioPharma

Dr. Chari has disclosed the following:
Consultant/Advisor: Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen Novartis, Millennium, Amgen
Research Grant: Array BioPharma, Celgene, Janssen, Novartis, Millennium, Onyx, Pharmacyclics

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

Supported by independent educational grants from Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Certificate Fee



The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; or Takeda Oncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu